Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.9950
-0.0450 (-4.33%)
At close: May 19, 2026, 4:00 PM EDT
1.030
+0.035 (3.52%)
After-hours: May 19, 2026, 6:07 PM EDT
Rein Therapeutics Employees
Rein Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
n/a
Profits / Employee
-$5,020,800
Market Cap
77.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -4 | -26.67% |
| Dec 31, 2023 | 15 | 9 | 150.00% |
| Dec 31, 2022 | 6 | -3 | -33.33% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| PolyPid | 75 |
| ImmuCell | 73 |
| eXoZymes | 32 |
| NeurAxis | 24 |
RNTX News
- 1 day ago - Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 4 days ago - Rein Therapeutics Quarterly report: Q1 2026 - Filings
- 19 days ago - Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 20 days ago - Rein Therapeutics provides update on RENEW clinical trial - TheFly
- 20 days ago - Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 21 days ago - Rein Therapeutics files to sell 30M shares of common stock - TheFly
- 21 days ago - Rein Therapeutics Registration statement: Registration filing - Filings
- 6 weeks ago - Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright - TheFly